- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01435265
Nurse Education in Subjects With Psoriasis Undergoing Treatment With Adalimumab
The Effectiveness of Nurse Education and Its Impact on Treatment Adherence in Subjects With Moderate to Severe Psoriasis Undergoing Treatment With Adalimumab
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This is a phase IV randomized, prospective open label study to asses the efficacy of an extended nurse eduction program in improving adherence to the prescribed treatment regimen in the treatment of moderate to severe psoriasis vulgaris. Twenty subjects, male or female, ages 18 and older in good health with moderate to severe chronic plaque type psoriasis for whom adalimumab is indicated according to the adalimumab prescribing information. All subjects must have a negative TB skin test according to prescribing guidelines. Subjects must be starting adalimumab for the first time, prescribed by their physician.
This is an open label trial. All subjects will be receiving adalimumab as prescribed by their physician. Half the group will be randomized to receive the additional nurse education program, the other half will receive the normal education materials provided by their physician.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
North Carolina
-
Winston-Salem, North Carolina, Stati Uniti, 27157
- Wake Forest University Health Sciences
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Subjects must be male or female, 18 years of age or greater, in good health with moderate to severe plaque psoriasis for whom adalimumab is indicated according to the adalimumab prescribing information.
- All subjects must have a negative TB skin test according to prescribing guidelines.
- Subjects must be starting adalimumab for the first time, prescribed by their dermatologist.
- Must give written informed consent.
- Subject must be adult males or non-pregnant , non-lactating females.
- Female subjects of childbearing potential must state that they are using measures to avoid conception through active means including, abstinence, oral contraceptives, intrauterine device, Depo-Provera, Norplant, tubal ligation, or vasectomy of the partner in a monogamous relationship.
- Subjects may not be on concomitant systemic medications for their psoriasis such as methotrexate, acitretin, etretinate, cyclosporine, prednisone ot other biological agents or receiving phototherapy at the baseline visit, but no specific washout of these treatments will be required.
- There is no washout for topical medications. Stable dosing of topical medications may be used throughout the duration of the study.
Exclusion Criteria:
- Subjects who have any skin condition or disease that may require concurrent therapy or may confound the evaluation.
- Subjects who have a history of hypersensitivity to adalimumab or history of hypersensitivity to any of the formulation components will be excluded from the study.
- Female subjects who are not postmenopausal for at least one year, surgically sterile or willing to practice effective contraception during the study. Nursing mothers, pregnant women and women planning to become pregnant while on study are to be excluded.
- Current enrollment in any research study involving an investigational drug.
- Serious local infection or systemic infection within the three months prior to the first dose of investigational drug.
- Treatment with another investigational drug within one month prior to study drug administration.
- Concurrent treatment with systemic retinoids, systemic steroids, methotrexate, cyclosporine, azathioprine, thioguanine, etanercept, efalizumab, infliximab or mofetil or other systemic immunosuppressant agents.
- Any active or history of HIV, Hepatitis or tuberculosis
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Ricerca sui servizi sanitari
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Comparatore attivo: Normal Nurse Education
Subjects receive normal nurse education materials provided by their physician.
|
Standard-of-care education from a dermatology nurse on the proper use of adalimumab
|
Sperimentale: Additional Nurse Education-
Subjects will receive additional nurse education beyond the normal education materials provided by their physician
|
Standard-of-care education from a dermatology nurse on the proper use of adalimumab
Additional education from a nurse on the use of adalimumab.
This will include discussion of the pre-study evaluation with the subject, design of an Individual Educational Plan based on the pre-study evaluation, and a 30-60 minute educational session with the nurse educator at each study visit.
Additional information concerning the benefits of the local support group and National Psoriasis Foundation will be provided.
Additional education on self-injection and the opportunity to practice self-injection under the supervision of a nurse will also be provided.
Subjects will also receive reminder phone calls to take each scheduled dose.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Change in Psoriasis Area Severity Index (PASI-75)
Lasso di tempo: Baseline, 1 month, 3 months, 6 months, 9 months, 12 months
|
The Psoriasis Area Severity Index measures severity of psoriasis on a 0-6 scale for head, trunk, upper extremities, and lower extremities and amount of erythema, infiltration, and desquamation for each area.
An overall score of 0-72 for the whole body is calculated from the observed severity values.
Outcomes will be reported in terms of PASI 75, or number of participants showing at least 75% reduction in PASI score from baseline.
Only final PASI 75 will be reported.
|
Baseline, 1 month, 3 months, 6 months, 9 months, 12 months
|
Investigator's Global Assessment (IGA) of Psoriasis
Lasso di tempo: 12 months
|
Investigator's Global Assessment (IGA) is rated on a scale of 0 (clear) to 5 (very severe).
The outcome measure to be reported is the number of patients who reached a final IGA of 0 (clear) or 1 (almost clear).
|
12 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Adherence to Adalimumab Treatment
Lasso di tempo: Baseline to 12 months
|
Adherence measured by average days between doses used, as measured by a Medication Event Monitoring System (MEMS) cap on the disposal container for used syringes.
|
Baseline to 12 months
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Steven R Feldman, MD, PhD, Wake Forest University Health Sciences
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- IRB00009876
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Standard nurse education
-
University of Wisconsin, MadisonAurora Health CareTerminatoCancro al seno | Cancro colorettale | Cancro ai polmoni | Cancro alla prostataStati Uniti
-
Tokat Gaziosmanpasa UniversityCompletatoStigmatizzazione | Funzionalità | Supporto tra pari | Disturbi mentali cronici | Formazione sulle abilità psicosociali | IntuizioneTacchino
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development...Reclutamento
-
Assistance Publique - Hôpitaux de ParisSconosciutoCancro al seno | Chirurgia | Cancro della pelle | AmbulatorioFrancia
-
Centers for Disease Control and PreventionCompletatoInfezioni da HIV | Epatite CStati Uniti
-
University of Arkansas, FayettevilleNational Cancer Institute (NCI); University of California, Los Angeles; Thomas... e altri collaboratoriAttivo, non reclutanteMalattie prevenibili da vaccino | Papilloma-virus umanoStati Uniti
-
Li-Li ChenSconosciutoDiabete mellito di tipo 2Taiwan
-
VA Office of Research and DevelopmentCompletatoIpertensioneStati Uniti
-
Wake Forest University Health SciencesNational Center for Complementary and Integrative Health (NCCIH)Non ancora reclutamento